The In-Vitro Diagnostics Regulation (IVDR) is EU Regulation (EU) 2017/746, which governs the placing on the market, performance evaluation and surveillance of in-vitro diagnostic medical devices (IVDs) within the European Economic Area. It has replaced the former IVD Directive and has significantly tightened requirements: more products require the involvement of a notified body, performance evaluation becomes more systematic, and post-market surveillance and vigilance take on greater importance. For manufacturers, notified bodies, clinical trial partners and Regulatory Affairs, the IVDR is thus the central legal framework for diagnostics.
For CROs, the IVDR is relevant because it defines requirements for performance evaluation studies, data quality and regulatory documentation. While many practitioners from the pharmaceutical world orient themselves towards CTR 536/2014 and GCP, the IVDR has its own systematics. Nevertheless, principles such as data integrity, traceable processes and risk-based quality management are comparable in implementation.
Purpose and scope of the IVDR
The IVDR applies to IVDs such as reagents, test kits, calibrators, control materials, software as an IVD, and certain instruments, provided they serve in-vitro diagnostic purposes. It sets out how manufacturers demonstrate conformity, how products are classified, and what information must be provided to users. A key point is the intended purpose: it determines what a test may be used for (e.g. screening, diagnosis, monitoring) and in which target population. The intended purpose and claims must be reflected in the performance evaluation.
The Regulation also distinguishes between commercial products and certain in-house procedures. Special rules exist for health institutions, but these are subject to conditions (e.g. quality management and justification of why no equivalent CE-marked IVD is available). In practice, borderline cases – such as software components or laboratory-developed tests – are often regulatorily demanding.
Classification (A–D) and implications for notified bodies
A central element of the IVDR is risk-based classification into classes A, B, C and D. The higher the risk, the stricter the requirements and the more likely the involvement of a notified body. Under the IVDR, many products that were previously “self-certified” now require a notified body. This has practical consequences for timelines, resources and the strategic planning of performance evaluation studies.
Classification is based, among other things, on the risk to patient safety and public health. Class D includes, for example, tests of high importance for blood and organ donation safety or highly critical infectious disease diagnostics. For such products, additional requirements such as EU reference laboratory involvement are possible. Manufacturers must therefore develop an early regulatory roadmap that brings together classification, the conformity assessment route and the evidence strategy.
Performance evaluation: scientific validity, analytical and clinical performance
Performance evaluation is the cornerstone of the IVDR. It comprises three pillars: scientific validity (the association between an analyte and a clinical condition), analytical performance (e.g. sensitivity, specificity, accuracy, repeatability), and clinical performance (clinical sensitivity/specificity, predictive values, benefit in the target population). These elements are planned in a Performance Evaluation Plan and brought together in a Performance Evaluation Report. The requirements thus go significantly beyond the earlier, less structured evidence.
For study partners, this means: study design, sample management, statistics and data management must be aligned with the claims. Typical pitfalls are inadequate reference methods, bias in the sample cohort, or unrepresentative prevalences. The distinction between clinical performance and clinical benefit must also be documented cleanly so that notified bodies can follow the evidence.
Early end-to-end planning has proven effective in practice: which samples are needed, which reference tests count as the gold standard, how is blinding implemented, and which acceptance criteria define “passed performance”? Such details are not only scientifically relevant but also audit-critical, because they safeguard the reproducibility and traceability of the performance data.
Post-market surveillance and vigilance under the IVDR
After placing a product on the market, manufacturers must operate a PMS system, evaluate complaints, analyse trends, and initiate corrective measures where necessary. Depending on the class, periodic reports are required. Vigilance includes the reporting of serious incidents and field safety corrective actions. For IVDs in particular, signal assessment is complex, because errors in diagnostics do not always become immediately visible as an “incident” but can have significant clinical consequences.
In practice, PMS data are expected to feed back into the ongoing update of the performance evaluation. This turns the technical documentation into a “living” system. Manufacturers should therefore set up processes, responsibilities and data flows so that PMS, CAPA and performance evaluation are consistently integrated. Manufacturers should also align portfolio prioritisation and scheduling realistically with notified body capacities.
FAQ
What is the biggest difference between the IVDR and the former IVD Directive?
The IVDR tightens the requirements for classification, performance evaluation and the involvement of notified bodies. Many products require a formal conformity assessment procedure with external review for the first time.
Does every IVD require a performance study?
Not necessarily, but the manufacturer must demonstrate scientific validity as well as analytical and clinical performance. Depending on the product and available evidence, studies, literature data, or other evidence can be used, as long as they support the claims.
Why is post-market surveillance so important under the IVDR?
Because diagnostic performance can vary over time, across populations, and across usage scenarios. PMS delivers real-world data to continuously assess performance, risks and necessary corrective measures, and to keep the documentation up to date.
Regulatory references (selection)
- Regulation (EU) 2017/746 (IVDR) – central legal framework for in-vitro diagnostics in the EU
- MDCG guidance on IVDR implementation (e.g. classification, performance evaluation, PMS)
- ISO 13485 (QMS) and ISO 14971 (risk management) as common standards in the IVDR context